Geode Capital Management
NXTC icon

Geode Capital Management’s NextCure NXTC Stock Holding History

Geode Capital Management’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.9K Sell
29,905
-1,187
-4% -$8.77K ﹤0.01% 4256
2026
Q1 		$327K Buy
31,092
+7,935
+34% +$96.9K ﹤0.01% 3737
2025
Q4 		$329K Buy
23,157
+3,636
+19% +$37.7K ﹤0.01% 3738
2025
Q3 		$114K Buy
19,521
+379
+2% +$1.98K ﹤0.01% 4095
2025
Q2 		$106K Sell
19,142
-540
-3% -$2.9K ﹤0.01% 4045
2025
Q1 		$113K Buy
19,682
+189
+1% +$1.67K ﹤0.01% 4002
2024
Q4 		$180K Buy
19,493
+848
+5% +$12.5K ﹤0.01% 3936
2024
Q3 		$307K Buy
18,645
+2,318
+14% +$42.7K ﹤0.01% 3760
2024
Q2 		$312K Buy
16,327
+1,768
+12% +$34.4K ﹤0.01% 3750
2024
Q1 		$390K Hold
14,559
– – ﹤0.01% 3697
2023
Q4 		$199K Hold
14,559
– – ﹤0.01% 3945
2023
Q3 		$225K Buy
14,559
+1,427
+11% +$27.2K ﹤0.01% 3933
2023
Q2 		$284K Sell
13,132
-910
-6% -$17.9K ﹤0.01% 3889
2023
Q1 		$249K Hold
14,042
– – ﹤0.01% 3939
2022
Q4 		$237K Sell
14,042
-27
-0.2% -$621 ﹤0.01% 4005
2022
Q3 		$464K Sell
14,069
-182
-1% -$9.28K ﹤0.01% 3760
2022
Q2 		$803K Buy
14,251
+1,600
+13% +$83.6K ﹤0.01% 3520
2022
Q1 		$737K Buy
12,651
+734
+6% +$45.9K ﹤0.01% 3757
2021
Q4 		$858K Buy
11,917
+204
+2% +$17.1K ﹤0.01% 3782
2021
Q3 		$947K Buy
11,713
+436
+4% +$38.2K ﹤0.01% 3710
2021
Q2 		$1.09M Sell
11,277
-9,584
-46% -$981K ﹤0.01% 3553
2021
Q1 		$2.5M Buy
20,861
+5,294
+34% +$767K ﹤0.01% 3146
2020
Q4 		$2.04M Sell
15,567
-1,211
-7% -$156K ﹤0.01% 3076
2020
Q3 		$1.77M Sell
16,778
-275
-2% -$33.8K ﹤0.01% 2938
2020
Q2 		$4.39M Buy
17,053
+1,782
+12% +$678K ﹤0.01% 2411
2020
Q1 		$6.79M Buy
15,271
+1,648
+12% +$880K ﹤0.01% 1965
2019
Q4 		$9.21M Buy
13,623
+8,609
+172% +$4.32M ﹤0.01% 2071
2019
Q3 		$1.86M Sell
5,014
-441
-8% -$143K ﹤0.01% 2978
2019
Q2 		$980K Buy
+5,455
New +$1.13M ﹤0.01% 3245

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Geode Capital Management's NXTC Position: Q2 2026 in Review

Geode Capital Management reduced its NextCure (NXTC) stake by 3.8% in Q2 2026, selling an estimated $8.77K and leaving 29,905 shares worth $47.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4256.

Geode Capital Management first reported a position in NXTC in Q2 2019 and has held it in 29 quarters since. The position peaked at $9.21M in Q4 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Geode Capital Management held 29,905 shares of NextCure worth $47.9K as of Q2 2026.
  • Geode Capital Management sold 1,187 NextCure shares in Q2 2026, an estimated $8.77K.
  • NextCure made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4256 holding.
  • Geode Capital Management first reported a position in NextCure in Q2 2019 and has held it in 29 quarters since.
  • Geode Capital Management's NextCure position peaked at $9.21M in Q4 2019.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.